Danielle M. Brander

5.9k total citations
85 papers, 932 citations indexed

About

Danielle M. Brander is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Danielle M. Brander has authored 85 papers receiving a total of 932 indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Genetics, 35 papers in Pathology and Forensic Medicine and 22 papers in Immunology. Recurrent topics in Danielle M. Brander's work include Chronic Lymphocytic Leukemia Research (78 papers), Lymphoma Diagnosis and Treatment (35 papers) and Immunodeficiency and Autoimmune Disorders (20 papers). Danielle M. Brander is often cited by papers focused on Chronic Lymphocytic Leukemia Research (78 papers), Lymphoma Diagnosis and Treatment (35 papers) and Immunodeficiency and Autoimmune Disorders (20 papers). Danielle M. Brander collaborates with scholars based in United States, Australia and United Kingdom. Danielle M. Brander's co-authors include Ian W. Flinn, Peter Sportelli, Hari P. Miskin, Andrea Sitlinger, David B. Bartlett, Anthony R. Mato, Howard A. Burris, John G. Kuhn, Swaroop Vakkalanka and Manish R. Patel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Danielle M. Brander

80 papers receiving 921 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Danielle M. Brander United States	17	705	550	218	210	209	85	932
Vesselina Goranova‐Marinova Bulgaria	14	473 0.7×	351 0.6×	307 1.4×	168 0.8×	686 3.3×	44	1.1k
Kerstin Allen United States	13	467 0.7×	472 0.9×	261 1.2×	248 1.2×	116 0.6×	18	754
Jennifer Orchard United Kingdom	12	590 0.8×	435 0.8×	99 0.5×	286 1.4×	145 0.7×	16	742
András Rosta Hungary	9	386 0.5×	416 0.8×	65 0.3×	179 0.9×	71 0.3×	19	588
Christine I. Chen Canada	11	290 0.4×	207 0.4×	425 1.9×	83 0.4×	527 2.5×	55	769
Gaetano Vitelli Italy	14	298 0.4×	158 0.3×	308 1.4×	154 0.7×	130 0.6×	28	673
J.J. Sotto France	11	186 0.3×	238 0.4×	179 0.8×	125 0.6×	148 0.7×	17	565
Abelardo Bárez Spain	17	309 0.4×	175 0.3×	386 1.8×	156 0.7×	513 2.5×	42	918
Daniela Hoehn United States	15	188 0.3×	219 0.4×	276 1.3×	49 0.2×	257 1.2×	50	674
H Urbańska-Ryś Poland	12	197 0.3×	156 0.3×	111 0.5×	99 0.5×	133 0.6×	24	449

Countries citing papers authored by Danielle M. Brander

Since Specialization

Citations

This map shows the geographic impact of Danielle M. Brander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danielle M. Brander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danielle M. Brander more than expected).

Fields of papers citing papers by Danielle M. Brander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danielle M. Brander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danielle M. Brander. The network helps show where Danielle M. Brander may publish in the future.

Co-authorship network of co-authors of Danielle M. Brander

This figure shows the co-authorship network connecting the top 25 collaborators of Danielle M. Brander. A scholar is included among the top collaborators of Danielle M. Brander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danielle M. Brander. Danielle M. Brander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wierda, William G., David G. Maloney, Saad S. Kenderian, et al.. (2024). CLL-184 Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S346–S346. 3 indexed citations

Wierda, William G., David G. Maloney, Saad S. Kenderian, et al.. (2024). Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S180–S180. 1 indexed citations

Davids, Matthew S., Danielle M. Brander, Yesid Alvarado, et al.. (2024). A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies. Blood Advances. 9(4). 820–832. 3 indexed citations

Huntington, Scott F., Stephen J. Schuster, Wei Ding, et al.. (2023). DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study. American Journal of Hematology. 98(5). 739–749. 7 indexed citations

Ryan, Christine E., Danielle M. Brander, Paul M. Barr, et al.. (2023). A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia. 37(4). 835–842. 2 indexed citations

Eradat, Herbert, Jennifer A. Woyach, Ian W. Flinn, et al.. (2023). Updated follow‐up of BELLWAVE‐001: an open‐label, single‐arm, phase 1/2 study of the efficacy and safety of nemtabrutinib for the treatment of B‐cell malignancies. Hematological Oncology. 41(S2). 565–567. 1 indexed citations

Artese, Ashley, Andrea Sitlinger, Erik D. Hanson, et al.. (2022). Effects of high-intensity interval training on health-related quality of life in chronic lymphocytic leukemia: A pilot study. Journal of Geriatric Oncology. 14(1). 101373–101373. 5 indexed citations

Sitlinger, Andrea, Erwin Garcia, Margery A. Connelly, et al.. (2022). Associations of clinical and circulating metabolic biomarkers with low physical fitness and function in adults with chronic lymphocytic leukemia. Frontiers in Oncology. 12. 933619–933619. 3 indexed citations

Sitlinger, Andrea, Erwin Garcia, Tiffany M. Stewart, et al.. (2021). Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL). Cells. 10(5). 1165–1165. 6 indexed citations

10.

Stephens, Deborah M., Anna Moseley, Brian T. Hill, et al.. (2021). Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG S1925; NCT#04269902). Blood. 138(Supplement 1). 2630–2630. 1 indexed citations

11.

Ruppert, Amy S., Allison M. Booth, Wei Ding, et al.. (2021). Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 35(10). 2854–2861. 10 indexed citations

12.

Sitlinger, Andrea, Erik D. Hanson, Carl F. Pieper, et al.. (2021). A pilot study of high-intensity interval training in older adults with treatment naïve chronic lymphocytic leukemia. Scientific Reports. 11(1). 23137–23137. 20 indexed citations

13.

Ujjani, Chaitra S., Anthony R. Mato, Brian T. Hill, et al.. (2020). <p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. SHILAP Revista de lepidopterología. Volume 10. 1–5. 6 indexed citations

14.

Eichenberger, Emily M., Jennifer L. Saullo, Danielle M. Brander, et al.. (2019). A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy. Medical Mycology Case Reports. 27. 17–21. 9 indexed citations

15.

Kennard, Kaitlin, John C. Byrd, John M. Pagel, et al.. (2018). A U.S.-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts).. Journal of Clinical Oncology. 36(15_suppl). 7532–7532. 1 indexed citations

16.

Davids, Matthew S., Haesook T. Kim, Danielle M. Brander, et al.. (2017). A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. Blood. 130. 496–496. 8 indexed citations

17.

Sung, Anthony D., Carlos M. de Castro, Thomas W. LeBlanc, et al.. (2017). Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia. Blood. 130. 3853. 2 indexed citations

18.

Strati, Paolo, Mark C. Lanasa, Timothy G. Call, et al.. (2016). Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. The Lancet Haematology. 3(9). e407–e414. 12 indexed citations

19.

Brander, Danielle M., David A. Rizzieri, Jon P. Gockerman, et al.. (2013). Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. Leukemia & lymphoma. 54(12). 2627–2630. 5 indexed citations

20.

Brander, Danielle M. & Ernst Beinder. (2007). Auswirkungen der Periduralanästhesie (PDA) auf das Geburtserlebnis. Zeitschrift für Geburtshilfe und Neonatologie. 211(2). 76–81. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact